Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426173 | PMC |
| http://dx.doi.org/10.4103/ijo.IJO_2090_21 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Experience with Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Age-Related Macular Degeneration.
Am J Ophthalmol
September 2025
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. Electronic address:
Purpose: To report on the real-world experience of using intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) in age-related macular degeneration (AMD).
Design: Retrospective interventional case series.
Methods: Eyes with symptomatic GA secondary to AMD were treated with 15mg of intravitreal pegcetacoplan and participated in an ongoing prospective swept-source optical coherence tomography angiography (SS-OCTA) imaging study.
Short-term efficacy of faricimab switch on retinal exudative signs in patients requiring frequent anti-VEGF injections : A real-life study.
Eur J Ophthalmol
September 2025
Department of Ophthalmology, APHM, Hôpital Nord, Marseille, France.
ObjectiveTo evaluate the efficacy of switching from anti-vascular endothelial growth factor (VEGF) to faricimab in reducing exudative signs in age-related macular degeneration (AMD) patients receiving regular injections (every 8 weeks or less) without restarting a standard induction regimen.MethodsThis retrospective, observational, multicenter study included patients with exudative AMD previously treated with aflibercept 2 mg or ranibizumab every ≤8 weeks and switched to faricimab while maintaining their previous injection interval. The first follow-up visit occured after switching to faricimab, with a single injection, and corresponded to the pre-existing injection interval.
View Article and Find Full Text PDFAntidepressant Use and Incidence and Progression of Age-Related Macular Degeneration in a National United States Database.
Am J Ophthalmol
August 2025
Department of Ophthalmology, Virginia Commonwealth University, Richmond, Virginia, USA. Electronic address:
Objective: To evaluate the association between antidepressant use and the risk of developing non-exudative and exudative age-related macular degeneration (AMD), as well as the progression from non-exudative to exudative AMD, in patients using selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), or tricyclic antidepressants (TCAs).
Design: Retrospective clinical cohort study.
Subjects: Patients aged ≥40 years identified from the TriNetX database (October 2004-October 2023).
Single-cell transcriptome and surfaceome profiling of the adult human retinal pigment epithelium.
Stem Cell Reports
August 2025
Neural Stem Cell Institute, 150 New Scotland Ave., Albany, NY 12208, USA.
The retinal pigment epithelium (RPE) is a pigmented monolayer of cells beneath the neural retina that supports photoreceptor cell function essential for vision. Our study explores the diversity of adult human RPE subpopulations and associated implications for retinal biology. Employing cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq), we identified distinct RPE cell subpopulations characterized by unique single-cell transcriptomic and surface protein signatures.
View Article and Find Full Text PDFMorphologic changes of the double-layer sign during anti-vascular endothelial growth factor therapy in eyes with neovascular age-related macular degeneration.
Int Ophthalmol
August 2025
Hikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-BuildingKita-ku, Sapporo, 060-0807, Japan.
Purpose: To evaluate longitudinal morphologic changes of the double-layer sign (DLS) on optical coherence tomography (OCT) in eyes with neovascular age-related macular degeneration (nAMD) presenting with exudative macular neovascularization (eMNV) undergoing anti-vascular endothelial growth factor (VEGF) therapy.
Methods: This retrospective study included 207 consecutive treatment-naïve eyes (207 patients) with nAMD presenting with eMNV and a DLS treated with intravitreal anti-VEGF injections and were followed for ≥ 12 months. All eyes received 3 monthly loading injections followed by either treat-and-extend (TAE) or pro re nata (PRN) retreatment, per predefined criteria.